Perrigo Company plc PRGO is scheduled to report first-quarter 2024 results on May 7, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 3.61%. Let’s see how things have shaped up for this announcement. Factors at Play The Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.1 billion, while the same for earnings stands at 24 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels. Perrigo reports its results under the following segments — Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI). While we expect first-quarter sales in the CSCA segment to have suffered a decline due to lower net product sales in the United States, performance in the CSCI segment is expected to have been aided by products added through its HRA Pharma acquisition, partially offset by unfavorable currency movements. The Zacks Consensus Estimate and our model estimate for CSCA sales stand at $654 million and $656 million, respectively. For sales in the CSCI segment, both the Zacks Consensus Estimate and our model estimate are pegged at $439 million. Perrigo reported higher net price realization for its products through strategic price increases in recent quarters. The improving price trend will likely be reflected in first-quarter sales, contributing to the top line. Investors are likely to be curious about potential product launches this year. We also expect management to provide an update on the expectedimpact of macroeconomic pressures in 2024. Earnings Surprise History Perrigo’s shares have gained 2.00% year to date compared with the industry’s 2.4% rise. Zacks Investment Research Image Source: Zacks Investment Research The company’s earnings performance has been decent over the trailing four quarters. Its earnings beat estimates in three of the last four quarters and missed the mark on one occasion, registering an earnings surprise of 6.47% on average. Perrigo Company plc Price and EPS Surprise Perrigo Company plc Price and EPS Surprise Perrigo Company plc price-eps-surprise | Perrigo Company plc Quote Earnings Whispers Our proven model does not predict an earnings beat for Perrigo this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Earnings ESP: Perrigo has an Earnings ESP of 0.00% as both the Most Accurate Estimate and Zacks Consensus Estimate are pegged at 24 cents. Zacks Rank: Perrigo currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank stocks here. Stocks to Consider Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle. Akero Therapeutics AKRO has an Earnings ESP of +28.89% and a Zacks Rank #3. Akero Therapeutics’ stock has lost 16.0% year to date. AKRO beat earnings estimates in two of the last four quarters while missing the mark on the other two occasions. On average, Akero delivered a negative earnings surprise of 2.28% in the last four quarters. argenx ARGX has an Earnings ESP of +10.00% and a Zacks Rank #3. argenx’s stock has lost 2.0% year to date. ARGX beat earnings estimates in two of the last four quarters and missed the mark on one occasion while meeting the mark on another. On average, argenx witnessed an earnings surprise of 14.18% in the last four quarters. ARGX will report first-quarter 2024 results on May 9. Sarepta Therapeutics SRPT has an Earnings ESP of +108.99% and a Zacks Rank #3. Sarepta Therapeutics’ shares have increased 33.6% in the year-to-date period. Earnings of SRPT beat estimates in each of the last four quarters, delivering an average earnings surprise of 464.56%. Sarepta will report first-quarter 2024 results on May 1, after market close. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Perrigo Company plc (PRGO):Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT):Free Stock Analysis Report argenex SE (ARGX):Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...